Sign in

    OrthoPediatrics Corp (KIDS)

    Financials

    Updated May 8, 2025, 8:43 PM UTC
    Income Statement - MetricQ3 2017FY 2017Q1 2018Q2 2018Q3 2018FY 2018Q1 2019Q2 2019Q3 2019FY 2019Q1 2020Q2 2020Q3 2020FY 2020Q1 2021Q2 2021Q3 2021FY 2021Q1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024Q1 2025
    Net Revenue (USD, thousands)37,613.00148,73244,68552,802.0054,573.0052,667.00204,72752,411
    Cost of Revenue (USD, thousands)10,899.0037,47912,51112,003.0014,513.0017,102.0056,12914,149
    Gross Profit (USD, thousands)26,714.00111,25332,17440,799.0040,060.0035,565.00148,59838,262
    Sales and Marketing Expenses (USD, thousands)12,439.0051,40214,16916,593.0016,750.0016,784.0064,29616,572
    General and Administrative Expenses (USD, thousands)19,594.0075,42124,73027,329.0026,299.0024,431.00102,78930,280
    Restructuring Expenses (USD, thousands)------3,65340
    Research and Development Expenses (USD, thousands)2,747.0010,1962,9982,543.002,577.002,916.0011,0342,351
    Total Operating Expenses (USD, thousands)34,780.00138,00441,89746,465.0045,626.0049,620.00183,60849,243
    Operating Loss (USD, thousands)(8,066.00)(26,751)(9,723)(5,666.00)(5,566.00)(14,055.00)(35,010)(10,981)
    Interest Expense (Income), Net (USD, thousands)(303.00)(198)637261.00404.001,319.002,6211,126
    Other Expense (Income) (USD, thousands)(854.00)(2,261)--(63.00)1,035.001,068(1,644)
    Total Other Expenses (Income), Net (USD, thousands)(1,163.00)(5,439)613381.003,571.002,354.006,919(518)
    Net Loss Before Income Taxes (USD, thousands)(6,903.00)(21,312)(10,336)(6,047.00)(9,137.00)(16,409.00)(41,929)(10,463)
    Income Tax Benefit (Provision) (USD, thousands)(212.00)(338)(2,531)(18.00)(1,218.00)(340.00)(4,107)196
    Net (Loss) Income (USD, thousands)(6,691.00)(20,974)(7,805)(6,029.00)(7,919.00)(16,069.00)(37,822)(10,659)
    Balance Sheet - MetricQ3 2017FY 2017Q1 2018Q2 2018Q3 2018FY 2018Q1 2019Q2 2019Q3 2019FY 2019Q1 2020Q2 2020Q3 2020FY 2020Q1 2021Q2 2021Q3 2021FY 2021Q1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024Q1 2025
    Cash [USD, thousands]-----43,82043,82033,439
    Restricted cash [USD, thousands]1,9721,9721,9621,9631,9981,9571,9571,990
    Short-term investments [USD, thousands]49,25149,251-0---25,333
    Accounts receivable - trade, net [USD, thousands]34,61734,61736,27542,02842,82742,35742,35743,993
    Inventories, net [USD, thousands]105,851105,851112,689116,366120,934117,005117,005119,752
    Prepaid expenses and other current assets [USD, thousands]3,7503,7505,0564,4996,4897,0217,0217,552
    Total current assets [USD, thousands]226,496226,496203,725193,783248,312237,173237,173232,059
    Property and equipment, net [USD, thousands]41,04841,04848,72153,48254,76550,59650,59652,622
    Amortizable intangible assets, net [USD, thousands]69,27569,27570,38267,84865,95564,42764,42762,348
    Goodwill [USD, thousands]83,69983,69991,48190,51291,26293,84493,84493,673
    Other intangible assets [USD, thousands]15,28715,28718,79218,66918,74416,75216,75216,736
    Other non-current assets [USD, thousands]2,9402,9404,0846,46710,25610,41710,41712,812
    Total other assets [USD, thousands]171,201171,201184,739183,496186,217185,440185,440185,569
    Total assets [USD, thousands]438,745438,745437,185430,761489,294473,209473,209470,250
    Accounts payable - trade [USD, thousands]12,64912,64919,73617,00211,6478,9088,90814,199
    Accrued compensation and benefits [USD, thousands]11,32511,3259,77212,61613,22113,88813,88811,325
    Current portion of long-term debt with affiliate [USD, thousands]152,144152,144154156158160160162
    Current portion of acquisition installment payable [USD, thousands]10,14910,14910,3681,3041,3251,3471,3471,368
    Other current liabilities [USD, thousands]7,3917,3915,7908,4918,2749,6599,65910,451
    Total current liabilities [USD, thousands]41,66641,66645,82039,56934,62533,96233,96237,505
    Long-term term loan [USD, thousands]--9,5799,250---24,013
    Long-term convertible note [USD, thousands]----47,83147,91347,91348,040
    Long-term debt with affiliate, net of current portion [USD, thousands]611,763611,763572532491451451410
    Other long-term debt, net of current portion [USD, thousands]----244635635563
    Acquisition installment payable, net of current portion [USD, thousands]3,5513,5513,6132,3712,4122,4522,4522,493
    Deferred income taxes [USD, thousands]5,4835,4835,2024,7394,0253,3813,3813,389
    Other long-term liabilities [USD, thousands]1,1121,1121,8153,0074,7995,8925,8926,691
    Total long-term liabilities [USD, thousands]20,05420,05420,78119,89983,75084,68184,68185,599
    Total liabilities [USD, thousands]61,72061,72066,60159,468118,375118,643118,643123,104
    Common stock [USD, thousands]66666666
    Additional paid-in capital [USD, thousands]580,287580,287583,086593,087597,009600,897600,897604,989
    Accumulated deficit [USD, thousands](197,742)(197,742)(205,547)(211,576)(219,495)(235,564)(235,564)(246,223)
    Accumulated other comprehensive loss [USD, thousands](5,526)(5,526)(6,961)(10,224)(6,601)(10,773)(10,773)(11,626)
    Total stockholders' equity [USD, thousands]377,025377,025370,584371,293370,919354,566354,566347,146
    Total liabilities and stockholders' equity [USD, thousands]438,745438,745437,185430,761489,294473,209473,209470,250
    Cash Flow - MetricQ3 2017FY 2017Q1 2018Q2 2018Q3 2018FY 2018Q1 2019Q2 2019Q3 2019FY 2019Q1 2020Q2 2020Q3 2020FY 2020Q1 2021Q2 2021Q3 2021FY 2021Q1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024Q1 2025
    Net (loss) income [USD, thousands](6,691.00)(20,974)(7,805)(6,029.00)(7,919.00)(16,069.00)(37,822)(10,659)
    Depreciation and amortization [USD, thousands]5,187.0017,3855,0284,779.005,280.003,993.0019,0805,048
    Stock-based compensation [USD, thousands]2,747.0010,5262,7992,939.003,922.003,888.0013,5483,859
    Accretion of acquisition installment payable [USD, thousands]280.001,372281256.0062.0062.0066162
    Non-cash other [USD, thousands](1,722.00)(4,631)----90139
    Other (Operating Activities) [USD, thousands]--368(2,146.00)(1,273.00)3,366.00315(1,558)
    Net cash used in operating activities [USD, thousands](7,543.00)(27,046)(6,690)(6,092.00)(10,279.00)(3,987.00)(27,048)(4,156)
    Acquisition of Boston O&P, net of cash acquired [USD, thousands]--(20,693)0.00468.000.00(20,225)-
    Clinic acquisitions, net of cash acquired [USD, thousands]-----(2,407.00)(2,882)(220)
    Sale of short-term marketable securities [USD, thousands]23,864.00112,90423,47426,381.000.000.0049,855-
    Investment in private companies and purchases of licenses [USD, thousands]-(2,106)---(267.00)(647)(1,540)
    Purchases of property and equipment [USD, thousands](3,836.00)(16,878)(6,460)(6,684.00)(1,381.00)262.00(14,263)(4,227)
    Net cash provided by (used in) investing activities [USD, thousands]17,922.0041,677(3,679)19,697.00(26,768.00)(2,412.00)(13,162)(5,987)
    Payments on mortgage notes [USD, thousands](37.00)(144)(35)(36.00)(42.00)(39.00)(152)(39)
    Payments on clinic acquisition notes [USD, thousands]--(538)(390.00)0.00(180.00)(1,108)(87)
    Net cash provided by financing activities [USD, thousands]9,387.007,301(573)(4,269.00)58,518.00(541.00)53,135(126)
    Effect of exchange rate changes on cash [USD, thousands]1,029.006331,479(2,010.00)684.00(328.00)(175)(79)
    NET INCREASE IN CASH AND RESTRICTED CASH [USD, thousands]20,795.0022,565(9,463)7,326.0022,155.00(7,268.00)12,750(10,348)
    Cash paid for interest [USD, thousands]10.0042223537.00621.001,371.002,7521,269
    Transfer of instruments between property and equipment and inventory [USD, thousands](374.00)57117164.00685.00(546.00)420(461)
    Right-of-use assets obtained in exchange for lease liabilities [USD, thousands]706706--3,2208,9578,9571,682
    Deferred income taxes [USD, thousands](1,163)(1,163)(2,445)(2,955)(3,907)(4,736)(4,736)196
    Accounts receivable - trade [USD, thousands](9,724)(9,724)1,155(4,583)(5,178)(4,749)(4,749)(1,497)
    Inventories [USD, thousands](26,279)(26,279)(6,631)(10,420)(14,154)(13,197)(13,197)(1,906)
    Prepaid expenses and other current assets [USD, thousands]9494(953)(403)(2,134)(1,561)(1,561)(519)
    Accounts payable - trade [USD, thousands]1,4911,4916,5624,150(1,768)(4,280)(4,280)5,207
    Accrued expenses and other liabilities [USD, thousands]6,8526,852(5,049)959308537537(2,528)
    Cash and restricted cash, beginning of period [USD, thousands]10,46210,46233,02733,02733,02733,02733,02745,777
    Cash and restricted cash, end of period [USD, thousands]33,02733,02723,56430,89053,04545,77745,77735,429
    Revenue by Segment - in Millions of USDQ3 2017FY 2017Q1 2018Q2 2018Q3 2018FY 2018Q1 2019Q2 2019Q3 2019FY 2019Q1 2020Q2 2020Q3 2020FY 2020Q1 2021Q2 2021Q3 2021FY 2021Q1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024Q1 2025
    Trauma and Deformity--33.3037.77137.64236.39145.137.87
    Scoliosis--10.2013.68215.63515.6855.213.66
    Sports Medicine/Other--1.181.3491.2960.584.40.88
    Total Revenue--44.6952.80254.57352.63204.752.41
    Revenue by Geography - in Millions of USDQ3 2017FY 2017Q1 2018Q2 2018Q3 2018FY 2018Q1 2019Q2 2019Q3 2019FY 2019Q1 2020Q2 2020Q3 2020FY 2020Q1 2021Q2 2021Q3 2021FY 2021Q1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024Q1 2025
    United States28.26111.0134.30541.24942.71442.89161.1640.9
    International9.3537.7210.38011.55311.8599.7743.5611.5
    Total Revenue37.61148.7344.68552.80254.57352.67204.7352.4
    KPIs - Metric (Unit, Scale)Q3 2017FY 2017Q1 2018Q2 2018Q3 2018FY 2018Q1 2019Q2 2019Q3 2019FY 2019Q1 2020Q2 2020Q3 2020FY 2020Q1 2021Q2 2021Q3 2021FY 2021Q1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024Q1 2025
    Number of countries in which products are marketed and sold (countries)-70707070-75-
    Number of children impacted since inception (children)-710,0001,000,0001,000,0001,100,000-1,140,000-